Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial

Ivan Foeldvari,Tamás Constantin,Jelena Vojinovic,Gerd Horneff,Vyacheslav Chasnyk,Joke Dehoorne,Violeta Panaviene,Gordana Susic,Valda Stanevicha,Katarzyna Kobusińska,Zbigniew Żuber,Bogna Dobrzyniecka,Irina Nikishina,Brigitte Bader-Meunier,Luciana Breda,Pavla Dolezalova,Chantal Job-Deslandre,Ingrida Rumba-Rozenfelde,Nico M. Wulffraat,Ronald Pedersen,Jack F. Bukowski,Bonnie Vlahos,Alberto Martini,Nicolino Ruperto

Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial

2019

Background To describe the 6-year safety and efficacy of etanercept (ETN) in children with extended oligoarticular juvenile idiopathic arthritis (eoJIA), enthesitis-related arthritis (ERA), and psoriatic arthritis (PsA)

Keywords:

Etanercept
Dermatology
Psoriatic arthritis
Enthesitis-Related Arthritis
Immunology
Diabetes mellitus
Oligoarticular Juvenile Idiopathic Arthritis
Medicine
Rheumatology
Juvenile Arthritis Disease Activity Score
Oligoarthritis
Arthritis
Internal medicine
Clinical trial

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations